Insight Molecular Diagnostics Inc (IMDX) Stock Price, Quote & News

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 949 409 7600

Website: www.imdxinc.com

Address:

2 International Plaza Dr., Suite 510, Nashville, United States

JohnPDaly Jun. 22 at 6:13 PM

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/06-22-2026-190745705

0 · Reply

JohnPDaly Jun. 18 at 4:22 PM

$IMDX Wow.

1 · Reply

focafoca99 Jun. 11 at 8:48 PM

$IMDX released data showing its GraftAssure CM-score outperforms single‑metric dd‑cfDNA in kidney transplant rejection detection.

0 · Reply

JohnPDaly Jun. 11 at 8:31 PM

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/06-11-2026-211734810

0 · Reply

jackedmund99 Jun. 11 at 7:49 PM

$IMDX great analysis out of seeking alpha and comments 20+ target

0 · Reply

NY2CHI Jun. 11 at 6:08 PM

$IMDX added more here today. We’re about 2 months out from the 150 day guideline from the FDA…I think we bounce over $15 when approved. Jmho

0 · Reply

quiet_investor_ Jun. 11 at 4:29 PM

$IMDX it is clear that we have $5.75 floor

0 · Reply

JohnPDaly Jun. 10 at 12:59 PM

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress $IMDX https://finance.yahoo.com/sectors/healthcare/articles/imdx-highlight-house-transplant-testing-200500649.html

0 · Reply

jackedmund99 Jun. 10 at 10:57 AM

$IMDX news 06/09/26 IMDX /to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress Jun 09, 2026 Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specifically Major transplantation conference in Boston will create additional awareness about GraftAssure technology and its differentiation and potential applications iMDx to also announce sponsorship of a grant for researchers to evaluate economics of in-house, transplanted-organ-rejection testing

0 · Reply

JohnPDaly Jun. 9 at 1:51 PM

$IMDX bought more.

0 · Reply

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

Jun 16, 2026, 4:05 PM EDT - 8 days ago

Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Jun 11, 2026, 4:17 PM EDT - 13 days ago

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

Jun 9, 2026, 4:05 PM EDT - 15 days ago

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

May 13, 2026, 5:00 PM EDT - 6 weeks ago

Insight Molecular Diagnostics Earnings Call Transcript: Q1 2026

May 13, 2026, 5:00 PM EDT - 6 weeks ago

Insight Molecular Diagnostics Earnings release: Q1 2026

May 13, 2026, 5:00 PM EDT - 6 weeks ago

Insight Molecular Diagnostics Shareholder letter: Q1 2026

May 13, 2026, 5:00 PM EDT - 6 weeks ago

Insight Molecular Diagnostics Quarterly report: Q1 2026

May 13, 2026, 4:05 PM EDT - 6 weeks ago

IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization

May 13, 2026, 4:00 PM EDT - 6 weeks ago

Insight Molecular Diagnostics Slides: Investor presentation

May 6, 2026, 4:05 PM EDT - 7 weeks ago

iMDx to Release First Quarter 2026 Results on May 13, 2026

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Insight Molecular Diagnostics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Insight Molecular Diagnostics Proxy statement: Proxy filing

Apr 15, 2026, 9:30 AM EDT - 2 months ago

Insight Molecular Diagnostics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 8:00 AM EDT - 2 months ago

Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay

Mar 26, 2026, 5:00 PM EDT - 3 months ago

Insight Molecular Diagnostics Earnings Call Transcript: Q4 2025

Mar 26, 2026, 5:00 PM EDT - 3 months ago

Insight Molecular Diagnostics Shareholder letter: Q4 2025

Mar 26, 2026, 5:00 PM EDT - 3 months ago

Insight Molecular Diagnostics Annual report: Q4 2025

Mar 26, 2026, 5:00 PM EDT - 3 months ago

Insight Molecular Diagnostics Earnings release: Q4 2025

2026-03-26T20:51:47.000Z - 3 months ago

Insight Molecular Diagnostics submits GraftAssureDx for FDA review

2026-03-26T20:45:14.000Z - 3 months ago

Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year

Mar 26, 2026, 4:05 PM EDT - 3 months ago

IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

Mar 26, 2026, 4:00 PM EDT - 3 months ago

Insight Molecular Diagnostics Slides: Investor presentation

Mar 20, 2026, 8:00 AM EDT - 3 months ago

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference

2026-03-13T12:13:12.000Z - 3 months ago

Insight Molecular Diagnostics highlights publication of study on GraftAssure

Mar 13, 2026, 8:00 AM EDT - 3 months ago

Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score

2026-03-03T13:21:06.000Z - 4 months ago

Insight Molecular Diagnostics completes milestones advancing GraftAssureDx

Mar 3, 2026, 8:00 AM EST - 4 months ago

Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission

2026-02-17T13:50:59.000Z - 4 months ago

Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street

2026-02-11T13:23:15.000Z - 4 months ago

Insight Molecular Diagnostics prices 4.53M shares at $5.75 in direct offering

Feb 11, 2026, 8:00 AM EST - 4 months ago

iMDx Announces $26.0 Million Registered Direct Offering

2026-01-13T14:13:54.000Z - 5 months ago

Insight ‘congratulated’ STAR working group on organ health testing paper

Jan 13, 2026, 9:00 AM EST - 5 months ago

IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring

Jan 7, 2026, 4:05 PM EST - 6 months ago

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

2026-01-06T13:05:54.000Z - 6 months ago

Insight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs

Jan 6, 2026, 8:00 AM EST - 6 months ago

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

2026-01-05T12:11:39.000Z - 6 months ago

iMDx prepares for U.S. commercial launch of GraftAssureDx

Jan 5, 2026, 7:00 AM EST - 6 months ago

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion

2025-11-10T22:10:29.000Z - 8 months ago

Insight Molecular Diagnostics reports Q3 EPS (34c) vs. (98c) last year

Nov 10, 2025, 5:00 PM EST - 8 months ago

Insight Molecular Diagnostics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Insight Molecular Diagnostics Shareholder letter: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Insight Molecular Diagnostics Quarterly report: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Insight Molecular Diagnostics Earnings release: Q3 2025

Nov 10, 2025, 4:05 PM EST - 8 months ago

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

Nov 3, 2025, 4:05 PM EST - 8 months ago

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

Oct 13, 2025, 4:05 PM EDT - 9 months ago

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

2025-10-06T11:35:23.000Z - 9 months ago

Insight Molecular says kidney transplant patient achieved ‘immune reset’

Oct 6, 2025, 7:15 AM EDT - 9 months ago

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

2025-09-24T11:15:23.000Z - 9 months ago

Insight Molecular Diagnostics announces attendance at two industry conferences

Sep 24, 2025, 7:05 AM EDT - 9 months ago

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Sep 16, 2025, 7:00 AM EDT - 10 months ago

Insight Molecular Diagnostics Slides: Investor presentation

Sep 8, 2025, 5:00 PM EDT - 10 months ago

Insight Molecular Diagnostics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-09-08T11:25:06.000Z - 10 months ago

Insight Molecular Diagnostics announces novel registry database

Sep 8, 2025, 7:15 AM EDT - 10 months ago

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

2025-09-08T11:10:23.000Z - 10 months ago

Insight Molecular Diagnostics enrolls first patient in GraftAssureDx trial

Sep 8, 2025, 7:00 AM EDT - 10 months ago

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

Aug 26, 2025, 4:05 PM EDT - 10 months ago

iMDx to Participate in NYC Investment Conferences September 8 - 11

Aug 15, 2025, 4:00 PM EDT - 11 months ago